These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

94 related items for PubMed ID: 8620671

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. Zileuton, an oral 5-lipoxygenase inhibitor, directly reduces sebum production.
    Zouboulis ChC, Saborowski A, Boschnakow A.
    Dermatology; 2005; 210(1):36-8. PubMed ID: 15604543
    [Abstract] [Full Text] [Related]

  • 23. Quantification of the 5-lipoxygenase inhibitor zileuton in human plasma using high performance liquid chromatography-tandem mass spectrometry.
    Pian P, Labovitz E, Hoffman K, Clavijo CF, Rzasa Lynn R, Galinkin JL, Vinks AA, Malik P, Christians U.
    J Chromatogr B Analyt Technol Biomed Life Sci; 2013 Oct 15; 937():79-83. PubMed ID: 24029553
    [Abstract] [Full Text] [Related]

  • 24. Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma. A randomized controlled trial. Zileuton Clinical Trial Group.
    Israel E, Cohn J, Dubé L, Drazen JM.
    JAMA; 1996 Mar 27; 275(12):931-6. PubMed ID: 8598621
    [Abstract] [Full Text] [Related]

  • 25. Effect of hepatic impairment on the pharmacokinetics of a single dose of cilostazol.
    Bramer SL, Forbes WP.
    Clin Pharmacokinet; 1999 Mar 27; 37 Suppl 2():25-32. PubMed ID: 10702884
    [Abstract] [Full Text] [Related]

  • 26. The pharmacokinetics of bendazac-lysine and 5-hydroxybendazac, its main metabolite, in patients with hepatic cirrhosis.
    Rovei V, Escourrou J, Campistron G, Ego D, Thiola A, Ribet A, Houin G.
    Eur J Clin Pharmacol; 1988 Mar 27; 35(4):391-6. PubMed ID: 3197747
    [Abstract] [Full Text] [Related]

  • 27. Effect of hepatic impairment on the pharmacokinetics of atomoxetine and its metabolites.
    Chalon SA, Desager JP, Desante KA, Frye RF, Witcher J, Long AJ, Sauer JM, Golnez JL, Smith BP, Thomasson HR, Horsmans Y.
    Clin Pharmacol Ther; 2003 Mar 27; 73(3):178-91. PubMed ID: 12621383
    [Abstract] [Full Text] [Related]

  • 28. Hepatic peroxisomal and drug metabolizing activity in CD-1 mice after oral treatment with a novel 5-lipoxygenase inhibitor.
    Rodrigues AD, Machinist JM.
    Toxicol Appl Pharmacol; 1996 Apr 27; 137(2):193-201. PubMed ID: 8661344
    [Abstract] [Full Text] [Related]

  • 29. Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor.
    Lu P, Schrag ML, Slaughter DE, Raab CE, Shou M, Rodrigues AD.
    Drug Metab Dispos; 2003 Nov 27; 31(11):1352-60. PubMed ID: 14570767
    [Abstract] [Full Text] [Related]

  • 30. Stereoselective glucuronidation of zileuton isomers by human hepatic microsomes.
    Sweeny DJ, Nellans HN.
    Drug Metab Dispos; 1995 Jan 27; 23(1):149-53. PubMed ID: 7720519
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. A new concept for acne therapy: a pilot study with zileuton, an oral 5-lipoxygenase inhibitor.
    Zouboulis CC, Nestoris S, Adler YD, Orth M, Orfanos CE, Picardo M, Camera E, Cunliffe WJ.
    Arch Dermatol; 2003 May 27; 139(5):668-70. PubMed ID: 12756111
    [No Abstract] [Full Text] [Related]

  • 34. Clinical pattern of zileuton-associated liver injury: results of a 12-month study in patients with chronic asthma.
    Watkins PB, Dube LM, Walton-Bowen K, Cameron CM, Kasten LE.
    Drug Saf; 2007 May 27; 30(9):805-15. PubMed ID: 17722971
    [Abstract] [Full Text] [Related]

  • 35. Effects of hepatic impairment on the steady-state pharmacokinetics of etravirine 200 mg BID: an open-label, multiple-dose, controlled Phase I study in adults.
    Schöller-Gyüre M, Kakuda TN, De Smedt G, Woodfall B, Berckmans C, Peeters M, Hoetelmans RM.
    Clin Ther; 2010 Feb 27; 32(2):328-37. PubMed ID: 20206790
    [Abstract] [Full Text] [Related]

  • 36. Benefits from adding the 5-lipoxygenase inhibitor zileuton to conventional therapy in aspirin-intolerant asthmatics.
    Dahlén B, Nizankowska E, Szczeklik A, Zetterström O, Bochenek G, Kumlin M, Mastalerz L, Pinis G, Swanson LJ, Boodhoo TI, Wright S, Dubé LM, Dahlén SE.
    Am J Respir Crit Care Med; 1998 Apr 27; 157(4 Pt 1):1187-94. PubMed ID: 9563738
    [Abstract] [Full Text] [Related]

  • 37. Zileuton.
    McGill KA, Busse WW.
    Lancet; 1996 Aug 24; 348(9026):519-24. PubMed ID: 8757156
    [No Abstract] [Full Text] [Related]

  • 38. Effects of novel 5-lipoxygenase inhibitors on the incidence of pulmonary adenomas in the A/J murine model when administered via nose-only inhalation.
    Myrdal PB, Karlage K, Kuehl PJ, Angersbach BS, Merrill BA, Wightman PD.
    Carcinogenesis; 2007 May 24; 28(5):957-61. PubMed ID: 17114645
    [Abstract] [Full Text] [Related]

  • 39. Randomized trial of zileuton in patients with moderate asthma: effect of reduced dosing frequency and amounts on pulmonary function and asthma symptoms. Zileuton Study Group.
    DuBuske LM, Grossman J, Dubé LM, Swanson LJ, Lancaster JF.
    Am J Manag Care; 1997 Apr 24; 3(4):633-40. PubMed ID: 10169531
    [Abstract] [Full Text] [Related]

  • 40. Dose-proportional pharmacokinetics of a new 5-lipoxygenase inhibitor, ABT-761, in healthy volunteers.
    Wong SL, Drajesk J, Chang MS, Witt G, Awni WM.
    Biopharm Drug Dispos; 1998 Apr 24; 19(3):159-62. PubMed ID: 9569998
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 5.